CL2016000951A1 - Forma cristalina anhidra h de cabazitaxel; proceso de preparación; composición farmacéutica que la comprende; útil para tratar cáncer. - Google Patents

Forma cristalina anhidra h de cabazitaxel; proceso de preparación; composición farmacéutica que la comprende; útil para tratar cáncer.

Info

Publication number
CL2016000951A1
CL2016000951A1 CL2016000951A CL2016000951A CL2016000951A1 CL 2016000951 A1 CL2016000951 A1 CL 2016000951A1 CL 2016000951 A CL2016000951 A CL 2016000951A CL 2016000951 A CL2016000951 A CL 2016000951A CL 2016000951 A1 CL2016000951 A1 CL 2016000951A1
Authority
CL
Chile
Prior art keywords
cabazitaxel
pharmaceutical composition
preparation process
useful
crystalline form
Prior art date
Application number
CL2016000951A
Other languages
English (en)
Inventor
Walter Cabri
Daniele Ciceri
Luca Domenighini
Andrea Gambini
Federico Peterlongo
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49447494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000951(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indena Spa filed Critical Indena Spa
Publication of CL2016000951A1 publication Critical patent/CL2016000951A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMA CRISTALINA ANHIDRA DE CABAZITAXEL; COMPOSICION FARAMCEUTICA; Y SU PROCESO DE PREPARACION
CL2016000951A 2013-10-23 2016-04-21 Forma cristalina anhidra h de cabazitaxel; proceso de preparación; composición farmacéutica que la comprende; útil para tratar cáncer. CL2016000951A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20130189949 EP2865675A1 (en) 2013-10-23 2013-10-23 A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
CL2016000951A1 true CL2016000951A1 (es) 2016-11-25

Family

ID=49447494

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000951A CL2016000951A1 (es) 2013-10-23 2016-04-21 Forma cristalina anhidra h de cabazitaxel; proceso de preparación; composición farmacéutica que la comprende; útil para tratar cáncer.

Country Status (20)

Country Link
US (1) US9586919B2 (es)
EP (2) EP2865675A1 (es)
JP (2) JP2016534065A (es)
KR (2) KR20160063356A (es)
CN (1) CN105849093A (es)
AU (1) AU2014339222B2 (es)
BR (1) BR112016007646B1 (es)
CA (1) CA2928305C (es)
CL (1) CL2016000951A1 (es)
DK (1) DK3060556T3 (es)
ES (1) ES2645478T3 (es)
HU (1) HUE035010T2 (es)
IL (1) IL245260B (es)
MX (1) MX363334B (es)
PL (1) PL3060556T3 (es)
PT (1) PT3060556T (es)
RU (1) RU2672110C2 (es)
SG (1) SG11201603168WA (es)
SI (1) SI3060556T1 (es)
WO (1) WO2015058961A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017123760A1 (en) 2016-01-15 2017-07-20 Qun Sun Compositions and formulations including cabazitaxel and human serum albumin
US11413265B2 (en) 2018-04-20 2022-08-16 Zhuhai Beihai Biotech Co., Ltd. Formulations and compositions of Cabazitaxel
WO2020249507A1 (en) * 2019-06-11 2020-12-17 Indena S.P.A. Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
KR101266549B1 (ko) * 2006-10-20 2013-05-24 시노팜 싱가포르 피티이 리미티드 결정형 무수 도세탁셀을 제조하는 방법
FR2926551A1 (fr) * 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
JP2014514306A (ja) 2011-04-12 2014-06-19 プラス・ケミカルス・エスアー 固体形態のカバジタキセル及びその製造方法
EP2548905A1 (de) 2011-07-18 2013-01-23 Bayer MaterialScience AG Verfahren zur Aktivierung von Doppelmetallcyanidkatalysatoren zur Herstellung von Polyetherpolyolen
TWI526437B (zh) 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
WO2013088335A1 (en) 2011-12-13 2013-06-20 Aventis Pharma S.A. Crystalline form of cabazitaxel and process for preparing the same
EP2822932A2 (en) 2012-03-08 2015-01-14 IVAX International GmbH Solid state forms of cabazitaxel and processes for preparation thereof
CN102675257B (zh) 2012-05-10 2014-07-02 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN102898406B (zh) * 2012-11-02 2014-12-03 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法

Also Published As

Publication number Publication date
EP2865675A1 (en) 2015-04-29
US20160244420A1 (en) 2016-08-25
MX363334B (es) 2019-03-19
CN105849093A (zh) 2016-08-10
KR20210158417A (ko) 2021-12-30
MX2016005231A (es) 2016-08-11
RU2016115538A3 (es) 2018-06-14
WO2015058961A1 (en) 2015-04-30
PL3060556T3 (pl) 2018-01-31
CA2928305C (en) 2021-06-15
RU2016115538A (ru) 2017-10-26
CA2928305A1 (en) 2015-04-30
SI3060556T1 (sl) 2017-10-30
JP2019055989A (ja) 2019-04-11
JP6698803B2 (ja) 2020-05-27
EP3060556B1 (en) 2017-08-02
JP2016534065A (ja) 2016-11-04
AU2014339222A1 (en) 2016-05-12
BR112016007646A2 (pt) 2017-08-01
US9586919B2 (en) 2017-03-07
PT3060556T (pt) 2017-11-10
IL245260A0 (en) 2016-06-30
DK3060556T3 (en) 2017-09-04
AU2014339222B2 (en) 2017-12-14
RU2672110C2 (ru) 2018-11-12
BR112016007646B1 (pt) 2022-12-27
IL245260B (en) 2018-11-29
SG11201603168WA (en) 2016-05-30
EP3060556A1 (en) 2016-08-31
KR20160063356A (ko) 2016-06-03
ES2645478T3 (es) 2017-12-05
HUE035010T2 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
NI201600056A (es) Inhibidores de bromodominio
CR20150316A (es) Compuestos y sus métodos de empleo
IL243976B (en) kdm1a inhibitors for disease treatment
HK1207861A1 (en) Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1
HK1221646A1 (zh) 高劑量普利多匹定用於治療亨廷頓舞蹈症的用途
CL2015001990A1 (es) Compuestos de pirrolopirimidina substituidos, composiciones de los mismos, y métodos de tratamiento con los mismos.
ECSP14013284A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
MX2016007801A (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
HK1217289A1 (zh) 使用細菌治療癌症的組合物和方法
HK1222398A1 (zh) 治療伯克霍爾德氏菌感染症的組合物及方法
BR112013025415A2 (pt) métodos para aumentar eficácia de terapia de câncer de folr1
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
CL2015003049A1 (es) Variantes de pertuzumab y su evaluación
BR112015028115A2 (pt) métodos e composições para o tratamento de câncer
EP2958936A4 (en) METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE
CL2015002488A1 (es) Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen
CL2015000926A1 (es) Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios.
UY37017A (es) Inhibidores aza-bencimidazol de pad4
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
CL2015002712A1 (es) Cristales de laquinimod sódico y proceso para la preparación de ellos
BR112014026326A2 (pt) composição para tratamento de distúrbios metabólicos
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad